Shanghai Junshi Bioscience Co., Ltd.

This study tested whether a new injectable medication called JS005 can safely and effectively treat moderate to severe plaque psoriasis. It involved 747 adults who received either JS005 at one of two doses or a placebo injection. The main goal was to see how many patients achieve…

This study tested if adding a new immunotherapy drug called toripalimab to standard chemotherapy could better control advanced or returning nasopharyngeal cancer. About 289 patients with this type of throat cancer were randomly assigned to receive either the new drug combination …

This large, completed Phase 3 trial tested if a new two-drug combination works better than the standard single-drug treatment for advanced kidney cancer that has spread or cannot be removed by surgery. The study involved 421 adults who had not received prior drug treatment for th…

This study tested the safety and initial effectiveness of a new immunotherapy drug (JS004) when combined with an existing immunotherapy (toripalimab) and, for some patients, standard chemotherapy. It involved 119 adults with advanced non-small cell or small cell lung cancer that …

This study aimed to see if a drug called JS005 behaves the same way in the body when injected using a standard pre-filled syringe versus a newer automatic pre-filled syringe. It involved 272 healthy adult volunteers who received a single injection with one of the two syringe type…